Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome

Tadele Girum 1*, Ebrahim Muktar 1, Kifle Lentiro 1, Habtamu Wondiye 2 and Misgun Shewangizaw 3

Abstract

Introduction: The emergence of MDR-TB remained a major public health threat particularly in developing countries. With increased prevalence and complexity of treatment, the burden of MDR-TB challenged the country. It is of an important; the epidemiology of drug resistant TB is not well understood. There are few studies conducted to assess the prevalence, determinants and treatment outcome of MDR-TB with inconclusive finding. Therefore, we aimed to conduct a systematic review and meta-analysis on Epidemiology of MDR-TB in Ethiopia, So that policy makers and other stalk holders could have pooled evidence on the problem to make a decision.

Methods: The review was conducted through a systematic literature search of articles published between 1997 and 2017. Five bibliographic databases and libraries: PubMed/Medline, Global Health Database, Embase, the Cochrane Library, and African Index Medicus were used. After cleaning and sorting, analysis was performed using STATA version 11. The pooled rate of MDR-TB prevalence, determinants and treatment outcome was estimated with a random-effects model. Heterogeneity was assessed by the I² and publication bias through funnel plot.

Results: The 34 studies that were retained for final analysis enrolled a total of 7461 TB or MDR-TB patients. We found that 2.18% (95% CI 1.44–2.92%) of newly diagnosed and 21.07% (95% CI 11.47–30.67%) of previously treated patients have MDR-TB with overall prevalence of 7.24% (95% CI 6.11–8.37). History of previous treatment is the major determinant (pooled OR = 4.78 (95% CI 3.16–6.39)), while contact history and adherence also contributed. In this review the pooled death computed among 5 articles showed that 12.25% (95% CI 9.39–15.11%) of MDR-TB patients were died in the course of treatment. Complication, drug side effects and HIV infection were the main determinants for the death.

Conclusion and recommendation: The prevalence is by far higher than the previous reports. It is mainly associated with history of previous treatment along with contact history. However, the treatment outcomes are comparable with previous studies, yet it is a concern. Comorbidities, drug side effects and HIV sero-positivity were the determinants. Thus, proper treatment of drug susceptible TB and early detection and treatment of MDR-TB before complication develops along with prevention of drug side effect and contacts with MDR-TB cases are very important.

Keywords: MDR-TB, Tuberculosis, Drug resistance, Treatment outcome

* Correspondence: girumtadele@yahoo.com
1Department of Public health, college of Medicine and Health Sciences, Wolkite University, Wolkite City, Ethiopia
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Multidrug-resistant tuberculosis (MDR-TB) is a type of TB that is resistant to the two most effective first-line drugs; Rifampicin and Isoniazid. It results from primary infection or may develop in the course of a patient's treatment [1]. The occurrence of MDR-TB is mainly attributable to human errors that predispose for resistance development, although genetic factors are believed to contribute to certain extent [2, 3]. The principal patient-related factor that predispose to MDR-TB is non-adherence to drug susceptible TB treatment [4].

Globally, 4.1% of new cases and 19% of previously treated TB cases were estimated to have had multidrug-resistant TB in 2016. In the same year, there were an estimated 600,000 incident cases of MDR/RR-TB with cases of MDR-TB accounting for 82% of the total and there were an estimated 350,000 MDR/RR-TB cases among notified TB patients. However only 153,119 cases were confirmed which is much lower than the estimated cases because only 41% of TB cases have been tested for resistance. There were about 240,000 deaths from MDR/RR-TB in 2016 [5].

In 2016, the 30 high MDR-TB burden countries accounted for 89.7% of the global incident cases of MDR-TB. While India, China and the Russian Federation alone accounted 47% of the global burden. In Africa, where little data is available, an estimated 93,000 cases were emerged in 2016 with estimated incidence of 2.7% among new and 14% among previously treated cases, but the vast majority of them went un-diagnosed. Ethiopia is one of the 30 MDR-TB high-burden countries, with an estimated 5800 cases reported in 2016 with the prevalence rate of 2.7% among new cases and 14% among previously treated patients [5, 6].

Globally, 129,689 of the 153,119 notified cases of multidrug-resistant TB and rifampicin resistant TB (MDR/RR-TB) in 2016 were enrolled in treatment. It means 85% of diagnosed cases or only 22% of the estimated incident MDR/RR-TB cases initiated treatment by the year. Which shows improvement in coverage and access to MDR TB treatment; however the cure rate is low and on the other hand mortality, default and failure are high. Only 50% of the MDR-TB patients in the 2012 cohort of detected cases were successfully treated, 16% died, and 10% failed [7]. Similarly, 54% of MDR/RR-TB cases in the 2014 cohort have successful outcome by 2016 [5].

The emergence of MDR-TB is a threat for the populations of resource-limited countries. Generally, the low socioeconomic status of the people, high prevalence of infectious diseases and limited access to well-equipped health care facilities worsens the effect of MDR-TB. Furthermore, poor treatment outcomes, longer treatment time (about two years), higher treatment costs, and many more complications make MDR-TB a more complex disease than TB [8, 9].

The overall epidemiology of drug resistant TB is not well understood in Ethiopia [10–12]. Accordingly there are few studies conducted to assess the prevalence, determinants and treatment outcome of MDR-TB with inconclusive findings. There are also other researches with finding of null impact of determinants on the prevalence and treatment outcome of MDR-TB. Therefore we aimed to conduct a systematic review on the epidemiology of MDR-TB in Ethiopia to assess the prevalence, determinants and treatment outcome of MDR-TB. So that policy makers and other stalk holders could have pooled evidence on the problem to make a decision.

Methods
Literature search strategy
This systematic reviews and meta analyses was conducted in accordance to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses: guidance for reporting of systematic reviews and meta analyses) [13] through a systematic literature search of articles published between 1997 and 2017 containing information on MDR-TB prevalence, determinants and treatment outcome. Search engines, Electronic bibliographic databases and libraries: PubMed/Medline, Global Health Database, Embase, the Cochrane Library, African Index Medicus and Google scholar were used to retrieve articles published with in the study period. Combination of search terms: “Resistant TB”, “MDRTB”, “Isoniazid and rifampicin resistance”, “HIV and TB”, “Re-treatment and resistance”, “TB treatment” and the names of MDR-TB treatment hospitals were used with (AND, OR, NOT) Boolean (Search) Operators. In addition the reference lists of primary and pertinent review articles were also uploaded into an EndNote XI library (EndNote, Carlsbad, CA, USA) to identify cited studies not captured by the electronic search and after all checked for duplications.

Selection /eligibility criteria
Studies that reported the prevalence of MDR-TB among new and/or previously treated patients, studies which compared two groups or reported determinants and studies which reported treatment outcome of MDR-TB that conducted in Ethiopia and published in English language regardless of the design and setting were used. Studies were also eligible for the review regardless of their study time. Studies conducted among presumptive MDR-TB cases only were excluded from the analysis to minimize over reporting. However studies conducted in MDR-TB referral centers which included both presumptive and all other cases were included.
Operational definition
The following definition in accordance with the MDR-TB guide line [5, 14] were used in this meta-analysis

- Drug-resistant TB - TB that is resistant to any first-line anti-tuberculosis drug
- MDR-TB is TB that caused by strains of M.tuberculosis that are resistant to at least INH and RMP.
- MDR-TB among new cases (Primary drug resistance) is defined as resistance to isoniazid and rifampin drugs in patients that have never been treated for TB. This reflects person-to-person transmission of drug-resistant TB bacilli.
- MDRTB among previously treated TB patients (Acquired drug resistance) is defined as resistance to isoniazid and rifampin drugs in patients that have been treated for TB. This reflects drug resistance acquired during TB treatment but may also reflect infection or re-infection with resistant TB bacilli.
- Presumptive MDR-TB is as smear positive previously treated patients who define as relapse, return after default, and failure; new smear positive pulmonary TB patients whose sputum remains smear positive at month 2 or 3 of treatment; symptomatic close contacts of known MDR-TB patient, and new smear positive with Human Immunodeficiency Virus (HIV) infected patients.
- Medical complication: is a comorbid condition diagnosed as secondary diagnosis in tuberculosis patients

Outcome of interest
This review was intended to measure the prevalence of MDR-TB among newly and/or previously treated TB patients. MDR-TB prevalence was calculated for the total sample and stratified for new and re-treatment groups. The odds of possible determinants were calculated for two variables and for others it was summarized. Lastly treatment outcome was measured in terms of mortality, cure and default rate.

Data extraction and abstraction
The titles and abstracts derived through the primary electronic search were thoroughly assessed for possibility of reporting the intended outcome and filtered for potential eligibility. From each eligible research, the following information was extracted based on the preformed database (Excel, Microsoft, 2010) format: about author, characteristic of the study participants, studies (study design, cohort size, setting), prevalence of MDR-TB, Treatment outcome, year of publication, year of study start and end, eligibility criteria, etc. All data were extracted independently and in duplicate using a standardized extraction form. Returned abstracts were reviewed and full texts retrieved if they contained relevant information. Mean way, each selected research was assessed for methodological quality and possibility of bias.

Data analysis
After cleaning and sorting the final database was exported into Stata 11.0 for analysis (Stata, College Station, TX, USA). An outcome of interest was rate of MDR-TB among different groups, rate of mortality and their determinants. Estimate of MDR-TB prevalence was assessed for each study and standardized mean with 95% confidence interval was used. These were calculated with a random-effects model according to the DerSimonian and Laird method [15]. Heterogeneity was assessed by the I^2 and values greater than 50% considered representing significant heterogeneity. When heterogeneity between studies was found to be significant, pooled estimates were based on random-effect models and the Hedges method of pooling. Results were displayed visually in forest plots. Bias was investigated by construction of funnel plots and Analysis was performed using the ‘metan’ and related functions in STATA version 11 (College Station, TX).

Results
Studies included
Our initial electronic database search with the chosen search terms identified 924 citations in the form of abstract, bibliography and full text research. Out of these, 427 researches which do not match with our objectives were excluded after reviewing their titles and abstracts. Then the remaining citations were transferred to endnote and cleaned for duplications and 98 articles were identified for full text review. Of the 98 articles reviewed in full text, 34 articles [16–49] were retained for final analysis based on the inclusion-exclusion criteria and quality assessment and 64 studies were removed prior to analysis for different reasons: 21 studies reported the prevalence of drug resistance other than MDR, 27 removed for lack of clear outcomes, 13 removed for reporting outcome among Non-resistant TB cases, 3 overlapped with larger studies. The study selection process is presented in (Fig. 1).

Description of findings
The 34 studies that were retained for final analysis enrolled a total of 7461 TB or MDR-TB patients [16–49]. With duplicates (repeated count), 23 cross-sectional studies measured prevalence of MDR-TB among 3477 New and/or previously treated patients [16–38], 14 cross-sectional and case control studies assessed determinants of MDR-TB among 3534 patients [24, 26, 28, 32, 33, 35, 37–44] and the rest 5 cohort studies assessed the treatment outcome and its determinants among
1538 MDR-TB patients [45–49]. Except one, all the studies were institution based researches conducted in different regions of Ethiopia and published between 1997 and 2017 with English language. Thirteen studies were conducted in Addis Ababa, where two of the first MDR-TB treatment centers were located and the rest were conducted in other referral centers and TB treatment hospitals. Survey characteristics are described in (Table 1).

Prevalence of MDR-TB
Of the 23 researches which reported MDR-TB prevalence, 14 researches reported prevalence of MDR-TB among previously treated patients, 14 researches reported among New PTB patients, 20 reported any first line drug resistance, 17 measured prevalence of isoniazid (INH) resistance and 16 reported prevalence of Rifampicin resistance (Table 2).

Overall, the prevalence of MDR-TB ranged from 0.5 to 46.3%, with a pooled prevalence of 7.24% (95% CI 6.11–8.37) (The pooled estimate was from random effect analysis). The proportion of MDR-TB among all TB cases varies from place to place. Among the reviewed researches, six articles reported high prevalence of MDR-TB in the range of 10.2–46.3% [20–22, 26, 32, 38]; Three of them being reported in Addis Ababa [20–22]. The highest MDR-TB prevalence with a rate of 46.3% was reported by Abate et al. [22] in Addis Ababa among previously treated PTB patients and as high as a prevalence of 43% was also reported among New and Previously treated PTB patients by Agonaifar et al. [21] (Fig. 2).

Studies conducted in other parts of the country also reported similar results. A study conducted in south western Ethiopia indicated that 31.4% of previously treated PTB patients have MDR-TB [32]. Additionally, 11.8% of MDR-TB was reported by Hussein et al. in 2013 [26] and 10.2% by Brhane et al. in 2017 [38] among all cases. On the other hand, three of these studies reported MDR-TB prevalence of below 1% [17–19].

The pooled prevalence of MDR-TB among newly diagnosed TB cases was 2.18% (95% CI 1.44–2.92%) (Fig. 3). The highest prevalence among new cases was reported to be 11.8 by Hussien et al. [26]. The overall prevalence of MDR-TB among previously treated TB cases was 21.07% (95% CI 11.47–30.67%) (Fig. 4). The heterogeneity test indicated that there is statistical significant variation among pooled estimate of MDR-TB in previously treated cases and new cases. Therefore, the pooled estimate was from random effect analysis in both cases. The observed variation of MDR-TB prevalence among newly diagnosed and previously treated cases was statistically significant (P < 0.001).

In our review, 20 researches that enrolled a total of 3087 patients assessed the prevalence of any first line
anti TB drug resistance and 58.6% are found to be resistant. Of the 17 researches that assessed the prevalence of INH resistance, 51.4% were found to have resistant TB to INH. Similarly, 32.9% of the 2460 patients have Rifampicin resistance (Table 2).

**Determinants of MDR-TB**

The reviewed articles indicated that previous exposure to TB treatment, contact history to known MDR-TB cases and previous treatment outcome were known be associated with prevalence of MDR-TB [24, 26, 28, 32, 33, 35, 37–44]. In this review, MDR-TB was found to be significantly associated with a previous history of anti-TB drug treatment. The risk of having MDR-TB was about 5 times higher in individuals with a previous history of anti-TB treatment. Except Hussien et al.’s report [26], all of the 12 researches reported that previous treatment is positively associated with MDR-TB with a pooled odds of 4.78 (95% CI 3.16–6.39) (Fig. 5).

| Studies included in the review | Study area | Study population | Study design | Study period | No of patients |
|-------------------------------|------------|------------------|--------------|--------------|----------------|
| [16] Demissie et al. 1997 | Addis Ababa | New PTB patients | Cross-sectional study | 1994 | 167 |
| [17] Gebeeyehu, 2001 | Arsi Zone | PTB patients | Cross-sectional study | 1997–98 | 195 |
| [18] Bruchfeld, 2002 | Addis Ababa | PTB patients | Cross-sectional study | 2000 | 121 |
| [19] Asmamaw et al., 2008 | Addis Ababa | New PTB patients | Cross-sectional study | 2004–5 | 173 |
| [20] Meskel et al. 2008 | Addis Ababa | Previously treated PTB | Cross-sectional study | 2001–2 | 84 |
| [21] Agonafir, 2010 | Addis Ababa | PTB patients | Cross-sectional study | 2005–6 | 107 |
| [22] Abate et al., 2012 | Addis Ababa | Previously treated PTB | Retrospective | 2004–8 | 376 |
| [23] Abebe et al. 2012 | South western Ethiopia | New PTB patients | Cross-sectional study | 2010–11 | 136 |
| [24] Tessema et al. 2012 | North Ethiopia | PTB patients | Cross-sectional study | 2009 | 260 |
| [25] Yimer et al. 2012 | ARS major towns | New PTB patients | Cross-sectional study | 2008 | 93 |
| [26] Hussein et al. 2013 | Bahirdar, Fitche & Ambo | PTB patients | Cross-sectional study | 2011 | 102 |
| [27] Biadglegne et al. 2014 | Bahirdar, Gondar & Dessie | TB lymphadenitis | Cross-sectional study | 2012 | 226 |
| [28] Esmail et al. 2014 | Eastern ARS | PTB patients | Cross-sectional study | 2010–11 | 230 |
| [29] Daniel et al. 2014 | Debре Birhan | PTB patients | Cross-sectional study | 2013–14 | 40 |
| [30] Seyoum et al. 2014 | Eastern Ethiopia | New PTB patients | Cross-sectional study | 2011–13 | 357 |
| [31] Tekle et al. 2014 | Benishangul & Aw | PTB patients | Cross-sectional study | 2013–14 | 87 |
| [32] Abdella et al., 2015 | South western Ethiopia | Previously treated PTB | Cross sectional | 2012–13 | 79 |
| [33] Adane et al. 2015 | East Gojjam | PTB patients | Cross-sectional study | 2011–12 | 89 |
| [34] Maru et al. 2015 | Dessie | PTB patients | Cross-sectional study | 2012–13 | 118 |
| [35] Meekonnen et al. 2015 | North Gondar | PTB patients | Cross-sectional study | 2014 | 124 |
| [36] Ali et al. 2016 | South Ethiopia | PTB patients | Cross sectional | 2013 | 109 |
| [37] Hamussie et al. 2016 | Arsi Zone | PTB patients | Cross-sectional study | 2013–14 | 106 |
| [38] Brhane et al., 2017 | Jigjiga | PTB patients | Cross sectional | NR | 98 |
| [39] Mulisa et al. 2015 | Oromia Region | MDR & Non MDR TB | Case control study | 2013–14 | 439 |
| [40] Dessalegn et al. 2016 | Addis Ababa | MDR & Non MDR TB | Case control study | NR | 206 |
| [41] Hirpa et al. 2013 | Addis Ababa | MDR & Non MDR TB | Case control study | 2011–12 | 268 |
| [42] Deressa et al. 2014 | Addis Ababa | MDR & Non MDR TB | Case control study | 2013 | 384 |
| [43] Assefa et al. 2017 | Addis Ababa | MDR & Non MDR TB | Case control study | 2013 | 710 |
| [44] Tadesse et al. 2015 | Addis Ababa | MDR & Non MDR TB | Cross sectional | 2008–11 | 439 |
| [45] Molalign et al. 2015 | Addis Ababa & Gondar | MDR TB | Cohort | 2011–14 | 342 |
| [46] Alene et al. 2016 | North west Ethiopia | MDR TB | retrospective cohort | 2010–15 | 242 |
| [47] Getachew et al. 2013 | Addis Ababa | MDR TB | retrospective cohort | 2011–12 | 188 |
| [48] Meressa et al. 2015 | Addis Ababa | MDR TB | Cohort | 2009–14 | 612 |
| [49] Girum et al. 2017 | South Ethiopia | MDR TB | retrospective cohort | 2011–16 | 154 |

ARS- Amhara Regional state MDR- TB = Multidrug resistant tuberculosis
However, in this review HIV was not significantly associated with MDR-TB prevalence. Of the 11 studies which reviewed to evaluate the association between MDR-TB and HIV only 3 researches by Tadesse et al. [44], Mulisa et al. [39] and Assefa et al. [43] reported significant positive association. In contrast to these, another 3 researches [26, 40, 41] showed preventive association and 5 researches [24, 32, 33, 35, 38] showed non-significant positive association. Overall pooled odds of HIV was 1.17 (95% CI 0.43–1.91) which indicates a positive but insignificant association (Fig. 6).

In addition to these factors, exposure to a known MDR-TB case (Contact history) in Mulisa et al. [39], Assefa et al. [43] and Brhane et al. [38], treatment adherence and drug side effect in Hirpa et al. [41] previous treatment outcome in Meressa et al. [48] were found to have a positive association with MDR-TB in Ethiopia. However a pooled estimate was not computed due to the smaller number of studies which assessed each variable.

### Table 2: Prevalence of primary and multidrug resistance

| Studies included          | Sample size | New | Re-treated | Total | Primary drug resistance % | MDR % among |
|--------------------------|-------------|-----|------------|-------|---------------------------|-------------|
|                          |             |     |            |       | Any drug                  | INH         | RMP         | New | re-treatment | over all |
| Demissie et al. 1997     |             | 167 | 0          | 167   | 15.6                      | 8.4         | 1.8         | NR  | NR          | 1.2      |
| Gebeyehu, 2001           |             | 195 | 19         | 195   | 19.5                      | 7.6         | 0           | NR  | NR          | 0.5      |
| Bruchfeld, 2002          |             | 103 | 18         | 121   | 14                        | 8.3         | 2.5         | NR  | NR          | 0.8      |
| Asmamaw et al, 2008      |             | 173 | 0          | 173   | 21.4                      | 13.3        | 1.2         | NR  | NR          | 0.6      |
| Meskel et al, 2008       |             | 0   | 84         | 84    | 53.6                      | NR          | NR          | NR  | 26.2        | 26.2     |
| Agonafir, 2010           |             | 44  | 63         | 107   | 60.8                      | 54.2        | 43.9        | 2.3 | 71.4        | 43       |
| Abate et al, 2012        |             | 0   | 376        | 376   | 72.9                      | 56.1        | 46.5        | 46.3| 46.3        |
| Abebe et al, 2012        |             | 136 | 0          | 136   | 18.4                      | 13.2        | 2.2         | 1.5 | NR          | 1.5      |
| Tessema et al, 2012      |             | 214 | 46         | 260   | 15.8                      | 13.8        | 5.8         | 3.7 | 10.9        | 5        |
| Yimer et al, 2012        |             | 93  | 0          | 93    | 30.1                      | 20.4        | 3.2         | 1.1 | NR          | 1.1      |
| Hussein et al, 2013      |             | 93  | 9          | 102   | 36.3                      | 29.4        | 13.7        | 11.8| 11.1        | 11.8     |
| Biadglegne et al,2014    |             | 213 | 13         | 226   | NR                        | NR          | NR          | 1.4 | 0           | 1.3      |
| Esmael et al, 2014       |             | 165 | 65         | 230   | 33.5                      | NR          | NR          | 1.8 | 18.5        | 6.5      |
| Daniel et al, 2014       |             | NR  | NR         | 40    | NR                        | NR          | NR          | 6.3 | 12.5        | 7.5      |
| Seyoun et al, 2014       |             | 357 | 0          | 357   | 23                        | 14          | 2.8         | 1.1 | NR          | 1.1      |
| Tekle et al, 2014        |             | 75  | 12         | 87    | 16.5                      | 12.6        | 2.3         | 1.3 | 8.3         | 2.3      |
| Abdella et al, 2015      |             | 79  | 0          | 79    | 58.6                      | 51.4        | 32.9        | NR  | 31.4        | 31.4     |
| Adane et al, 2015        |             | 77  | 12         | 89    | 20.23                     | 6.7         | 5.6         | 1.3 | 16.7        | 3.4      |
| Maru et al, 2015         |             | 103 | 15         | 118   | 17.8                      | 13.55       | 0           | 0   | 13.3        | 1.7      |
| Mekonnen et al, 2015     |             | 88  | 36         | 124   | NR                        | NR          | NR          | 2.3 | 13.9        | 5.6      |
| Ali et al, 2016          |             | NR  | NR         | 109   | 24.77                     | 7.34        | 5.5         | NR  | NR          | 3.67     |
| Harnusse et al, 2016     |             | 85  | 21         | 106   | 21.7                      | 13.2        | 7.5         | 2.4 | 14.3        | 4.7      |
| Brhane et al, 2017       |             | 67  | 31         | 98    | 18.4                      | NR          | 8.2         | 4.5 | 22.6        | 10.2     |
| Weighted mean            |             | –   | –          | –     | 31.1                      | 21.65       | 13.4        | 2.18| 21.07*       | 7.24*    |
| Total N                  |             | 2527| 820        | 3477  | 3087                      | 2675        | 2460        | 2527| 820         | 3477     |

INH-Isoniazid, RMP-rifampicin, NR = Not reported * value indicates polled prevalence from random effect model

### Discussion

This study assessed the prevalence of MDR-TB among newly diagnosed and previously treated patients, Concerning the outcomes, this meta-analysis revealed that 8.4–13.9% of MDR-TB patient died during treatment and 25–64.7% were get cured, another 10–16.9% were completed treatment [45–49]. According to Molalign et al. [45] of the 342 MDR-TB patients 10.8% were died and the median survival time was 16 months. In another study 13% of patients were died and 54% were cured [46]. A research by Girum et al. [49] also reported that 8.4% of patients were died, 25.3% were cured and 16.9% completed their treatment. In this review the pooled death computed among 5 researches showed that 12.25% (95% CI 9.39–15.11%) of MDR-TB patients were died (Fig. 7). Presence of medical complication, drug side effect, HIV sero-positivity and baseline weight were the most common reasons for the death [47, 49].
- Fig. 2 Forest plot showing the prevalence of MDR-TB among the total samples

- Fig. 3 Forest plot showing the prevalence of MDR-TB among newly diagnosed TB cases
Fig. 4 Forest plot showing the prevalence of MDR-TB among previously treated cases

Fig. 5 The pooled odds of previous treatment on MDR-TB prevalence
identified possible determinants and evaluated treatment outcome by reviewing 34 researches conducted in Ethiopia. Within this review 23 researches were pooled together to measure prevalence of MDR-TB and 7.24% (95% CI 6.11–8.37) found to have MDR-TB with the rate of 2.18% (95% CI 1.44–2.92%) among new cases and 21.07% (95% CI 11.47–30.67%) among previously treated patients. History of previous treatment along with some other variables was the major determinants. During the course of treatment 12.25% (95% CI 9.39–
15.11%) of MDR-TB patients were died mainly associated with complications.

According to this meta-analysis, the pooled prevalence of MDR-TB among newly diagnosed patients was comparable to the finding of previous meta-analysis by Eshete et al. [50] where 2% (95% CI 1–2%) of newly diagnosed TB patients have MDR-TB. However, it is slightly higher than a previous meta-analysis report that was conducted in Sub-Saharan Africa countries where the prevalence among the new cases was 1.5% (95% CI 1.0–2.3) [51] and the national report of WHO estimate for Ethiopia [5, 52] and the report of national surveys in Benin [53]. On the other hand the prevalence of MDR-TB among new cases was lower than the first Ethiopian national TB survey report of 2.7% and the survey report of Mozambique and Rwanda [54–56].

The pooled prevalence of MDR-TB among previously treated patients was higher than both of the previously stated researches where 15% (95% CI 12 17%) of patients in Eshete et al. [50] and 10.3% (95% CI 5.8–17.4%) of patients in Asres et al. [51] have MDR-TB. Likewise, anti-tuberculosis survey in Ethiopia, Benin, Mozambique and Rwanda showed that the prevalence of MDR-TB among previously treated patients was 17.9, 11.1, 11.2 and 9.4% [53–56] respectively which is by far lower than our pooled estimate.

This discrepancy may be related to the inclusion of many researches conducted in MDR-TB referral centers which knowingly or unknowingly included presumptive MDR-TB cases where the prevalence of MDR-TB is higher. It is logical that patients who have treatment history and currently on treatment are more likely to have MDR-TB than previously treated patient recruited in the community where their TB was treated. There for inclusion of larger samples in hospital based studies particularly in MDR-TB referral centers increases the finding of MDR-TB cases. However in newly diagnosed cases weather they are recruited in the community or in hospitals the prevalence is similar, that is why national surveys and institutional studies have comparable results. In addition to this difference in base line burden, difference in settings and quality of care may have explained the difference [50, 51].

In line to many of the previous reports [50, 51] MDR-TB was highly associated to history of previous TB treatment (OR = 4.78 (95% CI 3.16–6.39). The odds of developing MDR-TB among previously treated patients was 8.11 (7.52, 8.74) and 5.69 (3.61–8.96) in Ethiopia [50] and Sub-Saharan countries [51] respectively. As previously treated patients have the chance to acquire a new infection and develop resistance through gene mutation while up on treatment the likely hood of having MDR-TB compared to newly diagnosed TB patient is higher [5, 51].

The association between HIV and MDR-TB was not conclusive. Over all pooled odds of HIV was 1.17 (95% CI 0.43–1.91) which is a positive but insignificant association. Tadesse et al. [44], Mulisa et al. [39] and Assefa et al. [43] reported significantly positive association between HIV infection and MDR-TB. However, a significant positive association between HIV and MDR-TB has not been reported from previous reviews in SSA [51] and study results in east Africa and Ethiopia [10, 22, 24, 38].

It is long been known that HIV suppress the human cellular immunity and shorten the period from TB infection to TB disease development [8–10]; however, its contribution to the development of drug resistant TB seems to be not significant.

According to the reports of Mulisa et al. [39], Assefa et al. [43] and Brhane et al. [38] exposure to a known MDR-TB case (Contact history) has a significant association with the prevalence of MDR-TB. It is also reported by Federal Ministry of Health of Ethiopia [57] that exposure to a known MDR-TB case along with history of using poor quality TB drugs and mal-absorption were found to have a positive association with MDR-TB in Ethiopia. Since one of the modes of transmission of MDR-TB is through droplet, a close contact history with a known MDR-TB patient carries higher risk for the development of the disease. Meanwhile, treatment adherence and drug side effect and previous treatment outcome were found to have a positive association with MDR-TB in Ethiopia [41, 48].

Overall, 65–80% of patients were completed, cured or alive on treatment throughout the period of follow up with in the reviewed researches [45–49] which met the WHO target of 75% [1] and it is higher than the achievement of most MDR-TB prevalent countries [5, 58]. Also multiples of recent systematic review and meta-analysis reported a lower success rate. Group based meta-analysis Reported pooled treatment success rate of 66.4% [59], also another individual patient based study review reported a success rate of lower than this fig. [60]. On the other hand some researches from Ethiopia and Haiti reported higher success rates [48, 61].

The proportion of death in our case is also comparable to many other studies [58–60]. However the treatment outcome from a cohort studies may differ depends on whether the research is an open cohort in which outcome may be experienced at the later phase of the treatment or closed cohort in which the outcome is experienced during or before the research is completed. In line to our report a result from a review of 35 articles and another individual patient review reported a death rate of greater than 10% [59, 60].

The treatment advancement through time, patient condition during admission, program organization, the setting and multitude of other factors may contribute.
significantly for difference in success rate. Generally in Ethiopia it was noted from WHO reports and previous studies that the success rate was higher [5]. Most researchers reported that poor outcome of MDR TB treatment is highly contributed by prevalence of HIV co-infection [45–49] and other medical complications. In addition to these, drug side effect and smaller baseline weight were significantly associated with mortality [49]. We have discovered the same relation in which the risk of death in HIV positive individuals was higher than sero-negatives. This is because during HIV infection the prevalence of co-infection, the probability of drug interaction and side effects and overall compliance will decrease which further increase mortality. Similarly, presence of complication contributes for mortality [47, 49].

The finding of this review may suffer from the fact that the research is from tuberculosis treatment centers their representativeness for the community is limited. The review was also limited to researches published in English and within the specified data sources as well as it is covering only a specific geographic areas, so that generalization for the country at large may be difficult. Due to institutional based nature of the primary researches inclusion of presumptive cases may be there, which could further increase the prevalent estimate.

Conclusion and recommendation:

The review showed that MDR-TB is continued to become a serious public health problem in Ethiopia. The prevalence is by far higher than the previous reports among previously treated patients. Meanwhile history of previous treatment along with contact history contributed for the development of the disease. The treatment outcomes reported in this review was comparable with previous studies, yet it is a concern. The main predictors of mortality among MDR-TB patients up on treatment were presence of comorbidities, adverse side effects, mal-absorption, HIV sero-positivity and smaller baseline weight. Thus, proper treatment of drug susceptible TB and early detection and treatment of MDR-TB before complication developed along with prevention of drug side effect and contacts with MDR-TB cases are very important.

Abbreviations

DST: Drug Susceptibility Testing; MDR: Multidrug Resistance; MDR-TB: Multidrug-Resistant Tuberculosis; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PTB: pulmonary Tuberculosis; RR: Rifampicin resistant; TB: Tuberculosis

Acknowledgments

All authors who provided us information whenever we contacted them.

Availability of data and materials

Please contact author for data requests.

Authors’ contributions

TG: Conceived the project, took the primary role in data acquisition, analysis, interpretation writing the manuscript, and publication of the project. All others: revised the project, involved in interpretation and manuscript preparation. Both authors revised the final draft of the manuscript. All authors read and approved the final manuscript.

Authors’ information

TG: Is Bsc/public health, MPH in Epidemiology and Biostatistics, Lecturer at Department of Public health, College of Medicine and Health Sciences, Wollicite University, Wollicite, Ethiopia.

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Public health, college of Medicine and Health Sciences, Wollicite University, Wollicite City, Ethiopia. 2Institute of Public health, college of Medicine and Health Sciences, Bahir Dar University, Bahir Dar City, Ethiopia. 3Department of Public health, college of Medicine and Health Sciences, Arba Minch University, Arba Minch City, Ethiopia.

Received: 25 January 2018 Accepted: 31 May 2018

Published online: 14 June 2018

References

1. World health organization. Tuberculosis MDR-TB & XDR-TB progress report; 2011.
2. WHO, Treatment of tuberculosis: Guidelines For national programs; Geneva: 2003.
3. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest, 2006;130:261–72.
4. Federal Ministry of Health of Ethiopia (FMoH), Participants’ manual: national comprehensive tuberculosis, leprosy and TB/HIV training for general health workers. In: Addis Ababa: FMOH; 2011.
5. World Health Organization. Global tuberculosis report 2017. Geneva, Switzerland: WHO press; 2017.
6. Federal Ministry of Health of Ethiopia (FMoH), Tuberculosis prevention and control programme: special issue for world TB day. 2011;3:17–37.
7. World Health Organization (WHO), Multidrug-resistant tuberculosis (MDR-TB) 2015 update. In: Geneva: WHO; 2015.
8. World Health Organization (WHO): Drug-resistant tuberculosis now at record levels. 2010.
9. World Health Organization (WHO); Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: WHO; 2008. WHO/HTM/TB/2008.394.
10. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O’Grady J, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Med Int Health. 2010;15(9):1052–66.
11. Amor YB, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14(9):1345–52.
12. Sosa AJ, Amábile-Cuevas CF, Byarugaba DK, Hseuh P-R, Karuki S, Okeke IN. Antimicrobial resistance in developing countries. New York: Springer; 2010.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
14. World Health Organization. Definitions and reporting framework for tuberculosis–2013 revision. Geneva: WHO press; 2013.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
16. Dessimie M, Gebeeyehu M, Berhanie Y. Primary resistance to anti-tuberculosis drugs in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis. 1997;1(11):64–7.
17. Gebeeyehu M, Lemma E, Eyob G. Prevalence of drug resistance tuberculosis in Arsi zone, Ethiopia. Ethiop J Health Dev. 2001;15:111–6.
18. Bruchfeld J, Aderaye G, Palme IB, Bjornvat B, Ghebremicael S, Hoffner S, Lindquist L. Molecular epidemiology and drug resistance of Mycobacterium
